KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for BioNTech SE (BNTX) over the last 8 years, with Dec 2024 value amounting to -$710.9 million.

  • BioNTech SE's Net Income towards Common Stockholders fell 30.31% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$516.0 million, marking a year-over-year decrease of 188.70%. This contributed to the annual value of -$710.9 million for FY2024, which is 171.03% down from last year.
  • BioNTech SE's Net Income towards Common Stockholders amounted to -$710.9 million in FY2024, which was down 171.03% from $1.0 billion recorded in FY2023.
  • BioNTech SE's Net Income towards Common Stockholders' 5-year high stood at $11.8 billion during FY2021, with a 5-year trough of -$710.9 million in FY2024.
  • In the last 3 years, BioNTech SE's Net Income towards Common Stockholders had a median value of $1.0 billion in 2023 and averaged $3.3 billion.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first spiked by 64,869.65% in 2021, then crashed by 171.03% in 2024.
  • Over the past 5 years, BioNTech SE's Net Income towards Common Stockholders (Yearly) stood at $18.1 million in 2020, then spiked by 64,869.65% to $11.8 billion in 2021, then fell by 18.25% to $9.6 billion in 2022, then tumbled by 89.60% to $1.0 billion in 2023, then plummeted by 171.03% to -$710.9 million in 2024.